title: Tp53 and its potential therapeutic role as a target in bladder cancer.
abstract: Despite more than 30 years of research on p53 resulting in >50,000 publications, we are now beginning to figure out the complexity of the p53 pathway, gene ontology and conformational structure of the molecule. Recent years brought great advances in p53 related drugs and the potencial ways in which p53 is inactivated in cancer. Areas covered: We searched for related publications on Pubmed and ClinicalTrial.gov using the following keywords 'p53, Tp53, p53 and bladder cancer, p53 and therapeutic target'. Relevant articles improved the understanding on p53 pathways and their potential as candidate to targeted therapy in bladder cancer. Expert opinion: Novel strategies developed to restore the function of mutants with chemical chaperones or by using compounds to improved pharmacokinetic properties are in development with potential to be applied in the oncology clinic. Other strategies targeting aberrantly overexpressed p53 regulators with wild-type p53 are also an active area of research. In particular, studies inhibiting the interaction of p53 with its negative regulators MDMX and MDM2 are an important field in drug discovery. Small molecules for inhibition of MDM2 are now in clinical trials process. However, personalized anticancer therapy might eventually advance through analyses of p53 status in cancer patients.
authors.affiliation: a Medical Oncology, Azienda Ospedaliera Universitaria Integrata , University of Verona , Verona , Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Ciccarese
authors.affiliation: b Medical Oncology , Azienda Ospedaliera Universitaria Integrata (A.O.U.I.) , Verona , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Massari
authors.affiliation: c Maimonides Biomedical Research Institute of Cordoba, Spain - Urology Department , Reina Sofía Hospital , Córdoba , Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Blanca
authors.affiliation: d Medical Oncology dU, Policlinico 'G.B. Rossi' , University of Verona , Verona , Italy.
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Tortora
authors.affiliation: e Pathological Anatomy , Polytechnic University of the Marche Region, School of Medicine, United Hospitals , Ancona , Italy.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Montironi
authors.affiliation: f Department of Pathology and Laboratory Medicine , Indiana University School of Medicine , Indianapolis , IN 46202 , USA.
authors.forename: Liang
authors.initials: L
authors.lastname: Cheng
authors.affiliation: e Pathological Anatomy , Polytechnic University of the Marche Region, School of Medicine, United Hospitals , Ancona , Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Scarpelli
authors.affiliation: g Histopathology and Molecular Diagnostics Service , Careggi University Hospital Florence , Florence , Italy.
authors.forename: Maria R
authors.initials: MR
authors.lastname: Raspollini
authors.affiliation: h Medical Oncology , Champalimaud Clinical Center , Lisbon , Portugal.
authors.forename: Nuno
authors.initials: N
authors.lastname: Vau
authors.affiliation: i Urology service , Champalimaud Clinical Center , Lisbon , Portugal.
authors.forename: Jorge
authors.initials: J
authors.lastname: Fonseca
authors.affiliation: j Department of Surgery and Pathology , Cordoba University Medical School, Cordoba, Spain and Champalimaud Clinical Center , Lisbon , Portugal.
authors.forename: Antonio
authors.initials: A
authors.lastname: Lopez-Beltran
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018797:Cell Cycle Proteins; D015195:Drug Design; D006801:Humans; D018832:Molecular Chaperones / Q000494:pharmacology; D058990:Molecular Targeted Therapy; D009687:Nuclear Proteins / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; C482775:MDM4 protein, human; D018832:Molecular Chaperones; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
keywords: P53; TP53; bladder cancer; oncotarget; personalized medicine